-17.4%
TOST vs MRNA
+511.3%
-528.7%
-46.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.1% | -2.2% | +2.3% | +0.1% |
| 7D | -3.4% | +5.5% | -8.9% | -3.5% |
| 30D | -2.4% | +158.7% | -161.2% | -4.0% |
| 3M | +34.6% | +182.1% | -147.5% | +32.4% |
| 6M | +15.2% | +151.8% | -136.6% | +14.6% |
| YTD | -4.4% | +393.6% | -398.0% | -8.4% |
| 1Y | -17.4% | +499.5% | -516.9% | -21.5% |
| All | -17.4% | +511.3% | -528.7% | -21.5% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling